Physician Search
 |
 |
| Consuelo Wilkins, MD, MSCI, Senior Vice President for Health Equity and Inclusive Excellence for Vanderbilt University Medical Center (VUMC) and Senior Associate Dean for Health Equity and Inclusive Excellence for Vanderbilt University School of Medicine, always knew she wanted to be a physician. "Health equity was built into everything I did, even if I didn’t know it or recognize it at the time," Wilkins said. "I have always learned and believed that people are the same — everyone deserves to be healthy, and everyone should have the best opportunities to take care of themselves and their families." Click below to learn more about health equity initiatives. https://momentum.vicc.org/2021/09/everyone-deserves-to-be-healthy/ |
Vanderbilt was the lead site for an NIH-funded, phase 2, multicenter influenza vaccine study in pediatric allogeneic hematopoietic stem cell transplant (HCT) recipients that may lead to a change in the current flu vaccine recommendations in this vulnerable population. Natasha Halasa, MD, MPH and colleagues recently published in the New England Journal of Medicine, that two doses of high-dose trivalent flu vaccine resulted in higher amounts of influenza-specific antibodies than two doses of standard dose quadrivalent vaccine. https://news.vumc.org/2023/03/02/high-dose-flu-vaccine-beneficial-for-pediatric-stem-cell-transplant-patients/ |
ALL-IN - Targeting Inflammation and Alloimmunity in Heart Transplant Recipients with Tocilizumab
Not Available
Schlendorf, Kelly
CRE-CHF0005
DEFINE-HT - DevelopmEnt of non-invasive cell-Free DNA to supplant INvasivE biopsy in Heart Transplantation
Not Available
III
Schlendorf, Kelly
CRE-CHF0010
CORDIO HearO - AN INTERNATIONAL, MULTICENTER, OBSERVATIONAL, SINGLE-ARM, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEAROTM SYSTEM
Not Available
Lindenfeld, Joann
CRE-CHF0011
LUX-Dx Heart Failure Sensors in an Insertable Cardiac Monitor System Clinical Study
Not Available
Lindenfeld, Joann
CRE-CHF0012
OCEANIC-AF - A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke
Not Available
III
Montgomery, Jay
CRE-ARR0018
Blood-based, Point-of-need Assessment of CAR-T Vector Load in DLBCL Patients Undergoing Axicabtagene Ciloleucel (axi-cel) Therapy: A Multi-Site Study
Lymphoma
Lymphoma
Lymphoma
N/A
Oluwole, Olalekan
VICC-IDCTT23426
